C07K 14/12
Mumps virus
Official title: Mumps virus; Measles virus
C07K14/12 (Mumps virus) appears on 7 US grants and 16 published applications in this corpus.
Search patents in C07K- Granted patents
- 7
- Published applications
- 16
- Assignees
- 8
- Inventors
- 16
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 1 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 2 |
| 2015 | 0 | 1 |
| 2016 | 2 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 2 |
| 2019 | 1 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 2 |
| 2022 | 2 | 1 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Mumps and measles virus immunogens and their use26 May 2026US 12,636,360 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Re-directed immunotherapy1 Feb 2022US 11,236,131 B2The University of Birmingham
- Treatment of cancer using recall antigens delivered by attenuated bacteria4 Jan 2022US 11,213,577 B2Albert Einstein College of Medicine
- Re-directed immunotherapy14 May 2019US 10,287,321 B2The University of Birmingham
- Re-directed immunotherapy2 Aug 2016US 9,402,916 B2The University of Birmingham
- Mumps and measles virus immunogens and their use20 Aug 2026US 2026/0240984 A1The United States of America, as represented by the Secretary, Department of Health and Human Ser.
- Vaccine antigens and use thereof29 Jan 2026US 2026/0027197 A1Morehouse School of Medicine
- Mumps and measles virus immunogens and their use23 Feb 2023US 2023/0053555 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Treatment of cancer using recall antigens delivered by attenuated bacteria28 Apr 2022US 2022/0125901 A1Albert Einstein College of Medicine
- Induced immunological response to cancerous cells using vectors containing viral genes22 Jul 2021US 2021/0222182 A1
Most cited
By later US patents
- Chimeric VEGF peptides5US 8,080,253 B2The Ohio State University Research Foundation · 2011
- Re-directed immunotherapy4US 9,402,916 B2The University of Birmingham · 2016
- Re-directed immunotherapy3US 9,358,282 B2The University of Birmingham · 2016
- Re-directed immunotherapy2US 11,236,131 B2The University of Birmingham · 2022
- Re-directed immunotherapy1US 10,287,321 B2The University of Birmingham · 2019